ZURICH (Reuters) - Europe's largest biotech company Actelion said it expects results of a key late-stage trial on heart and lung disease drug macitentan in the next few weeks after a strong Swiss franc and competition hit first-quarter profit. Actelion is trying to cut its dependence on its main product Tracleer, which accounts for around 90 percent of group sales and is facing growing competition from Gilead's rival drug Letairis. ... Courtesy of Yahoo News
No comments:
Post a Comment